Bracco Imaging has launched a new subsidiary called Blue Earth Therapeutics to advance the development of radiopharmaceutical technology.
Initially, Blue Earth Therapeutics is building a portfolio of precision-targeted radiopharmaceuticals focused on prostate cancer. In the future, it will expand to additional diseases in oncology.
Also, the subsidiary has exclusive rights to therapeutic applications of radiohybrid prostate-specific membrane antigen radiopharmaceutical technology. David Gauden, PhD, is CEO of Blue Earth Therapeutics.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
